Jump to ContentJump to Main Navigation

Cellular and Molecular Biology Letters

Editor-in-Chief: /

4 Issues per year


Impact Factor 2014: 1.593
5-year IMPACT FACTOR: 1.647

SCImago Journal Rank (SJR) 2014: 0.670
Source Normalized Impact per Paper (SNIP) 2014: 0.620
Impact per Publication (IPP) 2014: 1.843

VolumeIssuePage

Lipid changes occuring in the course of hematological cancers

1Department of Haematology, Wrocław Medical University, Pasteura 4, 50-367, Wrocław, Poland

2Academic Centre for the Biotechnology of Lipid Aggregates, Wrocław, Poland

3Department of Angiology, Arterial Hypertension and Diabetology, Wrocław Medical University, Borowska 213, 50-556, Wrocław, Poland

© 2008 University of Wrocław, Poland. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. (CC BY-NC-ND 3.0)

Citation Information: Cellular and Molecular Biology Letters. Volume 13, Issue 3, Pages 465–474, ISSN (Online) 1689-1392, DOI: 10.2478/s11658-008-0014-9, July 2008

Publication History

Published Online:
2008-07-07

Abstract

The relationship between plasma lipid levels and mortality from cardiovascular diseases has been shown in many studies, but there has been far less investigation into their relationship to non-cardiovascular diseases. The aim of this study was to investigate the lipid profile of individuals with hematological malignancies and its relationship to disease activity. 238 patients were included in the study: 84 with acute leukemia, 62 with non-Hodgkin lymphoma, 35 with Hodgkin’s lymphoma, 32 with multiple myeloma, and 25 with myeloproliferative syndrome. The HDL cholesterol level of the patients differed to that of the individuals in the control group in the active disease period for all the analyzed disorders, but only remained statistically significant in the acute leukemia and non-Hodgkin lymphoma groups during the remission period. Smaller differences were observed for the remaining lipid fractions, except for the triglyceride level, which increased in the active disease period in all the analyzed disorders except non-Hodgkin lymphoma. The most pronounced changes in the lipid fractions occurred in the HDL cholesterol level, and were the most remarkable for acute leukemia.

Keywords: Lipid profile; HDL-C; Hematological cancers

  • [1] Castelli, W.P., Garrison, R.J., Wilson, P.W., Abbott, R.D., Kalousdian, S. and Kannel, W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256 (1986) 2835–2738. http://dx.doi.org/10.1001/jama.256.20.2835 [CrossRef]

  • [2] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383–1389.

  • [3] Kreger, B.E., Anderson, K.M., Schatzkin, A. and Splansky, G.L. Serum cholesterol level, body mass index, and the risk of colon cancer. The Framingham Study. Cancer 70 (1992) 1038–1043. http://dx.doi.org/10.1002/1097-0142(19920901)70:5<1038::AID-CNCR2820700505>3.0.CO;2-M [CrossRef]

  • [4] Sherwin, R.W., Wentworth, D.N., Cutler, J.A., Hulley, S.B., Kuller, L.H. and Stamler, J. Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. JAMA 257 (1987) 943–948. http://dx.doi.org/10.1001/jama.257.7.943 [CrossRef]

  • [5] Fiorenza, A.M., Branchi, A. and Sommariva, D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int. J. Clin. Lab. Res. 30 (2000) 141–145. http://dx.doi.org/10.1007/s005990070013 [CrossRef]

  • [6] Musolino, C., Calabro, L., Bellomo, G., Cincotta, M., Di Giacomo, V., Pezzano, C., Loteta, B., Rizzo, V., Guglielmo, S. and Alonci, A. Lipid profile in hematologic neoplasms. Recenti Prog. Med. 93 (2002) 298–301.

  • [7] Dessi, S., Batetta, B., Pulisci, D., Accogli, P., Pani, P. and Broccia, G. Total and HDL cholesterol in human hematologic neoplasms. Int. J. Hematol. 54 (1991) 483–486.

  • [8] Scribano, D., Baroni, S., Pagano, L., Zuppi, C., Leone, G. and Giardina, B. Return to normal values of lipid pattern after effective chemotherapy in acute lymphoblastic leukemia. Haematologica 81 (1996) 343–345.

  • [9] Moschovi, M., Trimis, G., Apostolakou, F., Papassotiriou, I. and Tzortzatou-Stathopoulou, F. Serum lipid alterations in acute lymphoblastic leukemia of childhood. J. Pediatr. Hematol. Oncol. 26 (2004) 289–293. http://dx.doi.org/10.1097/00043426-200405000-00006 [CrossRef]

  • [10] Kuliszkiewicz-Janus, M., Tuz, M.A. and Baczyński, S. Application of 31P MRS to the analysis of phospholipid changes in plasma of patients with acute leukemia. Biochim. Biophys. Acta 1737 (2005) 11–15.

  • [11] Lorenc, J., Kozak-Michałowska, I. and Polkowska-Kulesza, E. Disorders of lipid and lipoprotein metabolism in patients with chronic lymphocytic leukemia. I. Preliminary evaluation of lipemia and HDL fractions in various stages of the disease. Przegl. Lek. 46 (1989) 713–718.

  • [12] Ginsberg, H.N., Le, N.A. and Gilbert, H.S. Altered high density lipoprotein metabolism in patients with myeloproliferative disorders and hypocholesterolemia. Metabolism 35 (1986) 878–882. http://dx.doi.org/10.1016/0026-0495(86)90232-5 [CrossRef]

  • [13] Gilbert, H.S. and Ginsberg, H. Hypocholesterolemia as a manifestation of disease activity in chronic myelocytic leukemia. Cancer 51 (1983) 1428–1433. http://dx.doi.org/10.1002/1097-0142(19830415)51:8<1428::AID-CNCR2820510817>3.0.CO;2-X [CrossRef]

  • [14] Ghalaut, V.S., Pahwa, M.B., Sunita and Ghalaut, P.S. Alteration in lipid profile in patients of chronic myeloid leukemia before and after chemotherapy. Clin. Chim. Acta 366 (2006) 239–428. http://dx.doi.org/10.1016/j.cca.2005.10.022 [CrossRef]

  • [15] Hachem, H., Favre, G., Ghalim, N., Puchois, P., Fruchart, J.C. and Soula, G. Quantitative abnormalities of lipoprotein particles in multiple myeloma. J. Clin. Chem. Clin. Biochem. 25 (1987) 675–679.

  • [16] Kuliszkiewicz-Janus, M. and Baczyński, S. Chemotherapy-associated changes in 31P MRS spectra of sera from patients with multiple myeloma. NMR Biomed 8 (1995) 127–132. http://dx.doi.org/10.1002/nbm.1940080308 [CrossRef]

  • [17] Kuliszkiewicz-Janus, M. and Baczyński, S. Application of 31P NMR spectroscopy to monitor chemotherapy-associated changes of serum phospholipids in patients with malignant lymphomas. Magn. Reson. Med. 35 (1996) 449–456. [CrossRef]

  • [18] van Leeuwen, H.J., Heezius, E.C., Dallinga, G.M., van Strijp, J.A., Verhoef, J. and van Kessel, KP. Lipoprotein metabolism in patients with severe sepsis. Crit. Care Med. 31 (2003) 1359–1366. http://dx.doi.org/10.1097/01.CCM.0000059724.08290.51 [CrossRef]

  • [19] Sakashita, A.M., Bydlowski, S.P., Chamone, D.A. and Maranhao RC. Plasma kinetics of an artificial emulsion resembling chylomicrons in patients with chronic lymphocytic leukemia. Ann. Hematol. 79 (2000) 687–690. http://dx.doi.org/10.1007/s002770000205 [CrossRef]

  • [20] Baroni, S., Scribano, D., Zuppi, C., Pagano, L., Leone, G. and Giardina, B. Prognostic relevance of lipoprotein cholesterol levels in acute lymphocytic and nonlymphocytic leukemia. Acta Haematol. 96 (1996) 24–28. http://dx.doi.org/10.1159/000203710 [CrossRef]

  • [21] Moran, C.S., Campbell, J.H. and Campbell, G.R. Human leukemia inhibitory factor upregulates LDL-C receptors on liver cells and decreases serum cholesterol in the cholesterol-fed rabbit. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 1267–1273. [CrossRef]

  • [22] Goncalves, R.P., Rodrigues, D.G. and Maranhao, R.C. Uptake of high density lipoprotein (HDL) cholesteryl esters by human acute leukemia cells. Leuk. Res. 29 (2005) 955–959. http://dx.doi.org/10.1016/j.leukres.2005.01.013 [CrossRef]

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Danitza Pradelli, Davide Soranna, Antonella Zambon, Alberico Catapano, Giuseppe Mancia, Carlo La Vecchia, and Giovanni Corrao
Cancer Medicine, 2015, Volume 4, Number 5, Page 770
[2]
Cliona M. McHale, Luoping Zhang, Qing Lan, Guilan Li, Alan E. Hubbard, Matthew S. Forrest, Roel Vermeulen, Jinsong Chen, Min Shen, Stephen M. Rappaport, Songnian Yin, Martyn T. Smith, and Nathaniel Rothman
Genomics, 2009, Volume 93, Number 4, Page 343
[3]
Hina Usman, Rida Rashid, Fatima Ameer, Areeb Iqbal, Muhammad Zaid, Shahida Hasnain, Hubert Kalbacher, and Nousheen Zaidi
Clinica Chimica Acta, 2015, Volume 444, Page 43
[4]
Wael Al-Zhoughbi, Jianfeng Huang, Ganapathy S. Paramasivan, Holger Till, Martin Pichler, Barbara Guertl-Lackner, and Gerald Hoefler
Seminars in Oncology, 2014, Volume 41, Number 2, Page 281
[5]
Liang Wang, Pei-dong Chi, Hao Chen, Jin Xiang, Zhong-jun Xia, and Yu-jing Zhang
Tumor Biology, 2014, Volume 35, Number 3, Page 2141
[6]
Hiroshi Fujita, Tamae Hamaki, Naoko Handa, Akira Ohwada, Junji Tomiyama, and Shigeko Nishimura
Journal of Clinical and Experimental Hematopathology, 2012, Volume 52, Number 2, Page 85
[7]
Jianfeng Huang, Suman Kumar Das, Pooja Jha, Wael Al Zoughbi, Silvia Schauer, Thierry Claudel, Veronika Sexl, Paul Vesely, Ruth Birner-Gruenberger, Dagmar Kratky, Michael Trauner, and Gerald Hoefler
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2013, Volume 1831, Number 10, Page 1555
[8]
Yana Vinogradova, Carol Coupland, and Julia Hippisley-Cox
BMC Cancer, 2011, Volume 11, Number 1, Page 409

Comments (0)

Please log in or register to comment.